These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 22270402

  • 1. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma.
    Yang B, Lu XC, Yu RL, Chi XH, Zhang WY, Zhu HL, Yuan J, Zhao P.
    Am J Med Sci; 2012 Apr; 343(4):337-41. PubMed ID: 22270402
    [Abstract] [Full Text] [Related]

  • 2. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
    Jabr FI.
    Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
    [Abstract] [Full Text] [Related]

  • 3. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.
    Abou Mourad Y, Taher A, Shamseddine A.
    Hematol J; 2003 Nov; 4(3):222-4. PubMed ID: 12764356
    [No Abstract] [Full Text] [Related]

  • 4. [Clinicopathological features of acute tumor lysis syndrome in elderly patients with malignant non-Hodgkin's lymphoma].
    Zhang WY, Yang B, Lu XC, Liu Y, Yang Y, Zhu HL.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):953-8. PubMed ID: 21867622
    [Abstract] [Full Text] [Related]

  • 5. [Clinical analysis of 18 cases with acute tumor lysis syndrome in children with B-cell lymphoma].
    Huang S, Yang J, Zhang R, Duan YL, Zhang YH.
    Zhonghua Er Ke Za Zhi; 2011 Aug; 49(8):622-5. PubMed ID: 22093429
    [Abstract] [Full Text] [Related]

  • 6. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, Pogliani EM, Pioltelli PE.
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [Abstract] [Full Text] [Related]

  • 7. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte.
    Lancet; 2011 Nov 26; 378(9806):1858-67. PubMed ID: 22118442
    [Abstract] [Full Text] [Related]

  • 8. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH.
    Eur J Haematol; 2015 Jun 26; 94(6):504-10. PubMed ID: 25288018
    [Abstract] [Full Text] [Related]

  • 9. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
    Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N.
    J Clin Oncol; 2014 Dec 20; 32(36):4127-33. PubMed ID: 25403207
    [Abstract] [Full Text] [Related]

  • 10. Tumor lysis syndrome.
    Cope D.
    Clin J Oncol Nurs; 2004 Aug 20; 8(4):415-6. PubMed ID: 15354929
    [No Abstract] [Full Text] [Related]

  • 11. [Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature].
    Simon Z, Illés A, Miltényi Z, Magyari F, Váróczy L, Péter N, Gergely L.
    Orv Hetil; 2012 Oct 21; 153(42):1658-66. PubMed ID: 23063898
    [Abstract] [Full Text] [Related]

  • 12. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A.
    Br J Haematol; 2014 Mar 21; 164(5):668-74. PubMed ID: 24274082
    [Abstract] [Full Text] [Related]

  • 13. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.
    Eur J Haematol; 2014 Mar 21; 92(3):204-10. PubMed ID: 24283206
    [Abstract] [Full Text] [Related]

  • 14. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
    Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M.
    J Clin Oncol; 2014 Oct 10; 32(29):3242-8. PubMed ID: 25135997
    [Abstract] [Full Text] [Related]

  • 15. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A, Boggiani D, Panebianco M, Vasini G, Salvagni S, Franciosi V, Ardizzoni A.
    Cancer; 2011 Mar 01; 117(5):964-73. PubMed ID: 20960528
    [Abstract] [Full Text] [Related]

  • 16. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
    Samochatova EV, Maschan AA, Shelikhova LN, Myakova NV, Belogurova MB, Khlebnikova OP, Shamardina AV, Ryskal OV, Roumiantseva JV, Konovalov DM, Dubrovina ME, Rumyantsev AG.
    J Pediatr Hematol Oncol; 2014 Jul 01; 36(5):395-401. PubMed ID: 23823112
    [Abstract] [Full Text] [Related]

  • 17. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N.
    J Clin Oncol; 2010 Dec 01; 28(34):5097-100. PubMed ID: 20837949
    [Abstract] [Full Text] [Related]

  • 18. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK.
    Acta Ophthalmol; 2013 Jul 01; 91 Thesis 5():1-27. PubMed ID: 24041159
    [Abstract] [Full Text] [Related]

  • 19. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

  • 20. Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma.
    Park LC, Lee HS, Shin SH, Im H, Ye BJ, Song MK, Oh SY, Lee SM, Lee WS, Kim YS.
    Acta Haematol; 2011 May 25; 125(4):230-6. PubMed ID: 21325812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.